What is the RAPP stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Rapport Therapeutics, Inc. have a median 12-month price target of $59, with estimates ranging from $50 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RAPP stock a buy right now?
Of the 13 analysts covering Rapport Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapport Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RAPP?
As at 15 Aug 2026, Rapport Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will RAPP stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +24.4% from the last close, and Ticker Nerd's factor model ranks Rapport Therapeutics, Inc. 42 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RAPP stock forecast for 2030?
No analyst covering Rapport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RAPP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $80 over the next 12 months.
How has RAPP stock performed over the past year?
Rapport Therapeutics, Inc. returned +217.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rapport Therapeutics, Inc. do?
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines that target specific neurocircuits in the brain through receptor-associated proteins (RAPs). The company addresses a fundamental challenge in neuromedicine by creating small molecule therapeutics that can selectively modulate disease-driving neural circuits, overcoming the indiscriminate effects of conventional neurological treatments that often result in limited efficacy and significant side effects.
What is the latest news on RAPP?
The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update". Rapport Therapeutics reported financial results for the quarter ending June 30, 2026, having initiated the RAP-219 Phase 3 program in focal onset seizures with FOCUS 1 and FOCUS 2 trials now enrolling patients. The company held $436.1 million in cash, cash equivalents and short-term investments, expected to fund operations into the second half of 2029, and noted ongoing pipeline progress across RAP-219 and RAP-641.
